SI9620022A - Uporaba melatonina za odvajanje od zasvojenosti - Google Patents

Uporaba melatonina za odvajanje od zasvojenosti Download PDF

Info

Publication number
SI9620022A
SI9620022A SI9620022A SI9620022A SI9620022A SI 9620022 A SI9620022 A SI 9620022A SI 9620022 A SI9620022 A SI 9620022A SI 9620022 A SI9620022 A SI 9620022A SI 9620022 A SI9620022 A SI 9620022A
Authority
SI
Slovenia
Prior art keywords
melatonin
drug
benzodiazepine
patient
formulation
Prior art date
Application number
SI9620022A
Other languages
English (en)
Slovenian (sl)
Inventor
Nava Zisapel
Original Assignee
Neurim Pharmaceuticals (1991) Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/381,535 external-priority patent/US6469044B1/en
Application filed by Neurim Pharmaceuticals (1991) Ltd. filed Critical Neurim Pharmaceuticals (1991) Ltd.
Publication of SI9620022A publication Critical patent/SI9620022A/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI9620022A 1995-02-01 1996-01-29 Uporaba melatonina za odvajanje od zasvojenosti SI9620022A (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/381,535 US6469044B1 (en) 1995-02-01 1995-02-01 Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
EP95303853A EP0724878B1 (de) 1995-02-01 1995-06-06 Verwendung von Melatonin zur Behandlung von Patienten die an Drogenabhängigkeit leiden
PCT/IB1996/000082 WO1996023496A1 (en) 1995-02-01 1996-01-29 Use of melatonin for treating patients suffering from drug addiction

Publications (1)

Publication Number Publication Date
SI9620022A true SI9620022A (sl) 1998-10-31

Family

ID=26140195

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9620022A SI9620022A (sl) 1995-02-01 1996-01-29 Uporaba melatonina za odvajanje od zasvojenosti

Country Status (22)

Country Link
JP (1) JP4516159B2 (de)
CN (1) CN1083263C (de)
AT (1) AT408188B (de)
AU (1) AU695366B2 (de)
BG (1) BG62876B1 (de)
BR (1) BR9607169A (de)
CZ (1) CZ291349B6 (de)
DK (1) DK176081B1 (de)
EE (1) EE03384B1 (de)
FI (1) FI119586B (de)
IS (1) IS1980B (de)
LU (1) LU90118B1 (de)
LV (1) LV11940B (de)
MD (1) MD1716C2 (de)
NO (1) NO312814B1 (de)
NZ (1) NZ298878A (de)
PL (1) PL183148B1 (de)
SI (1) SI9620022A (de)
SK (1) SK284521B6 (de)
TR (1) TR199700723T1 (de)
TW (1) TW483757B (de)
WO (1) WO1996023496A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4996803B2 (ja) 2000-01-05 2012-08-08 ニューリム ファーマシューティカルズ（１９９１）リミテッド 抗高血圧剤に対する抵抗性及び関連状態を処置する方法及び処方物
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
ES2646197T3 (es) 2012-01-26 2017-12-12 Vanda Pharmaceuticals Inc. Tratamiento de trastornos del ritmo circadiano
IL266159B1 (en) 2012-12-18 2024-03-01 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
WO2018078429A1 (en) * 2016-10-31 2018-05-03 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000073I1 (de) * 1991-05-09 2008-01-31 Neurim Pharma 1991 Melatonin enthaltene Arzneimittel
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico

Also Published As

Publication number Publication date
SK103097A3 (en) 1998-01-14
MD970254A (en) 1999-05-31
FI119586B (fi) 2009-01-15
MD1716C2 (ro) 2002-02-28
JP4516159B2 (ja) 2010-08-04
FI973185A (fi) 1997-09-30
TR199700723T1 (xx) 1998-02-21
CN1172431A (zh) 1998-02-04
IS4532A (is) 1997-07-25
LU90118B1 (fr) 1997-11-13
AU695366B2 (en) 1998-08-13
CN1083263C (zh) 2002-04-24
AT408188B (de) 2001-09-25
BG62876B1 (bg) 2000-10-31
EE9700166A (et) 1998-02-16
NO973531L (no) 1997-09-30
TW483757B (en) 2002-04-21
LV11940A (lv) 1998-01-20
IS1980B (is) 2005-01-14
PL321630A1 (en) 1997-12-08
PL183148B1 (pl) 2002-05-31
MX9705856A (es) 1998-07-31
JPH10513177A (ja) 1998-12-15
NO312814B1 (no) 2002-07-08
DK176081B1 (da) 2006-04-18
LV11940B (en) 1998-05-20
SK284521B6 (sk) 2005-05-05
FI973185A0 (fi) 1997-07-31
EE03384B1 (et) 2001-04-16
NZ298878A (en) 1999-05-28
BR9607169A (pt) 1997-11-11
DK89697A (da) 1997-07-30
ATA901396A (de) 2001-02-15
CZ240597A3 (cs) 1998-01-14
MD1716B2 (en) 2001-08-31
WO1996023496A1 (en) 1996-08-08
CZ291349B6 (cs) 2003-02-12
AU4457496A (en) 1996-08-21
BG101803A (en) 1998-04-30
NO973531D0 (no) 1997-07-31

Similar Documents

Publication Publication Date Title
EP0724878B1 (de) Verwendung von Melatonin zur Behandlung von Patienten die an Drogenabhängigkeit leiden
JP2003507420A (ja) 作用物質の組成物、クロニジンを含む前記組成物
EP1272177B1 (de) Methode und zusammensetzung zur behandlung von resistenz gegen antihypertensiva und verwandten zuständen
SI9620022A (sl) Uporaba melatonina za odvajanje od zasvojenosti
KR101000624B1 (ko) 멜라토닌을 포함하는 약제학적 제제
US6344487B1 (en) Treatment of insomnia
Pagot et al. Comparison of the efficacy and tolerability of zolpidem 20 mg and triazolam 0.5 mg in anxious or depressed insomniac patients
CA2211839C (en) Use of melatonin for treating patients suffering from drug addiction
Jackson et al. Temazepam (Restoril, Sandoz Pharmaceuticals)
Mendelson DRUGS WITH HYPNOTIC PROPERTIES
Conroy et al. Sleep and substance use and abuse
MXPA97005856A (en) Use of melatonine in the manufacture of unmedicament to deal with addiction to dro
Wurtman Ramelteon: a melatonin receptor agonist
Ayd The future of anxiolytic drug therapy

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20070905